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1. Introduction 
Neoadjuvant treatment of locally advanced rectal cancer patients provides undisputable 
advantages regarding local control (1; 2), and it seems to afford the benefit of survival in 
patients with preoperative complete regression (3; 4). Furthermore, local control is an 
important feature in life quality of rectal cancer patients. However, due to the perspicuous 
interests in oncological effects, the acute and moreover late side effects tend to be neglected. 
The consequence is that especially late side effects have probably been underestimated until 
now.  
Many patients would perceive a permanent stoma and loss of the anal sphincter as a stigma 
that lowers their self-esteem (5). Hence, sphincter preservation is a major request of the 
patients and developed to an important surgical concern. In fact, patients are willing to 
trade a considerable amount of survival to avoid a colostomy (6). And more than this, they 
are also disposed to trade survival in order to avoid chemotherapy (6). 
Though, with regard to oncological and surgical outcome control late results are important. 
For all patients quality of life matters are fundamental. This particularly counts for those 
patients who show an incomplete regression or none and therefore do have only limited 
benefit from the treatment.  
2. Acute side effects 
The TME trial was the first large study that compared additional preoperative radiation 
therapy to TME (Total Mesorectal Excision) surgery alone (1). To register the acute side 
effects the RTOG (Radiation Therapy Oncology Group) classification 0-5 was used. In 
general, RTOG 0 represents no complaints and RTOG 5 is a toxicity leading to death. Mild 
toxic effects are grade 1 and 2; ≥ grade 3 counts as severe toxic effect. The trial showed acute 
side effects in 26% of the patients within three months of the start of short course radiation 
therapy (7). It is noticeable in the precise description of the side effects that the most 
frequent complications were gastrointestinal followed by neurological. 13% of the patients 
showed gastrointestinal symptoms, most of them grade I or II; only one patient suffered 
from grade III and none of grade IV (7). It is interesting to know that the scoring system for 
neurological symptoms was additionally implemented one year after the beginning of the 
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trial because observations of acute plexopathy in the antecedent Swedish Rectal Cancer Trial 
were published in 1996 (8).  During the first full year of the 4-year trial, no neurological 
symptoms were recorded in any of the patients (7). In fact, the Swedish Rectal Cancer Trial 
also compared neoadjuvant short-course radiation with surgery alone; however, this trial 
was conducted in the era before TME. It has to be noticed that during the recruitment phase 
of the Swedish Rectal Cancer Trial, the radiation technique changed from three-beam to 
four-beam (8). The authors explicitly report that no plexopathy was observed after 
conventional fractionation of the radiotherapy (2Gy/d) but only after short-course 
hypofractionated 5x5Gy radiation (8).  
Neoadjuvant chemoradiation correlates more closely with higher acute toxicity than short-
course radiation (9); in fact, it seems to be less harmful than postoperative chemoradiation 
with regard to acute toxicity (2). Comparing preoperative chemoradiation and long-course 
radiation with 45 Gy it seems to be obvious that radiation is more tolerable in the acute 
phase (10; 11). Actually, in most studies only grade 3 and grade 4 toxicities are listed, though 
the higher rates of grade 1 and 2 toxicities are not mentioned.  
 
Reference No. of 
patients 
Therapy strategy Toxicity 
grade III-IV 
(%) 
P 
value 
Marijnen 
2002 
695 vs. 719 5x5 Gy versus TME 2.4 vs. 0   n.s. 
Bujko  
2004 
155 vs. 157 5x5 Gy versus 
preoperative 
chemoradiation (5-FU) 
3 vs. 18   0.001 
Bosset  
2004 
398 vs. 400 45 Gy versus 
preoperative 
chemoradiation (5-FU) 
37.7 vs. 54 * <0.005 
Gérard 
2006 
367 vs. 375 45 Gy versus 
preoperative 
chemoradiation (5-FU) 
2.7 vs. 14.6 <0.005 
Sauer  
2004 
404 vs. 394 Pre-  versus 
postoperative 
chemoradiation (5-FU) 
27 vs. 40   0.001 
Gérard 
2010 
293 vs. 291 Cap vs. CapOx 
preoperative 
chemoradiation 
10.9 vs. 25.4 <0.001 
Cap: capecitabine; CapOx: capecitabine and oxaliplatin 
Table 1. Acute toxicity ≥ grade III (*toxicities ≥ grade II) in randomised trials.  
An impression of the difference is given in the publication of the EORTC 22921 study that 
listed all toxicities ≥ grade 2 and which thereby obtained a toxicity rate of 37.7 resp. 54% 
comparing 45 Gy with chemoradiation (11). The exclusive subsumption of grade 3 and 4 
toxicities of neoadjuvant treatment obtains a toxicity rate below 20% (Table 1). It should be 
noted that in a direct comparison of 5-FU versus capecitabine in a phase III trial, 
capecitabine showed to constitute significantly more hand-footsyndrome (31 vs. 2%) but less 
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leukopenia (25 vs. 35%) (12). Gastrointestinal and skin complications were no different 
between the arms.  
The addition of oxaliplatin to neoadjuvant treatment, either with 5-FU treatment or 
capecitabine, significantly increased the acute toxicity (particularly diarrhoea) three-fold and 
2.5-fold, respectively (13; 14). However, toxicity could be interpreted as feasible as particular 
grade III toxicities were recorded in not more than 15% of the patients. It was disappointing, 
however, that the rates of complete response did not change in both trials (13; 14). 
Unfortunately, there are no other randomised phase III trials that have compared different 
CRT regimens. 
A pooled analysis of three phase I/II trials of patients treated with or without additional 
cetuximab saw no difference in question of acute toxicity (15).  
3. Postoperative complications 
Looking at the postoperative complications one can notice that reporting of them is 
performed on an irregular basis concerning the definition of some complications as well as 
whether they are reported at all. Few randomised studies (2; 7; 14) report in detail on 
perioperative complications while others outline the overall rate of complications (Tables 
2/3). However, the interpretation of surgical and other complications is complex, even in 
the case of detailed reports. By way of example, the TME trial meticulously reports a 
significantly higher rate of postoperative complications in irradiated patients (7). 
Nevertheless, the rate of all surgical complications is the same for irradiated and non-
irradiated patients, although it differs for those with abdominoperineal resection. This is 
caused by the rate of perineal wound dehiscence that is increased following neoadjuvant 
radiation, while the rate of anastomotic leakages is no different between the groups. In 
addition, cardiac and psychological complications that are significantly more frequent in 
irradiated patients aggravate the higher postoperative complication rate (7). 
With regard to the risk of perineal wound dehiscence, the results of the different studies are 
inconsistent. While it is significantly increased for short-course radiation and 
chemoradiation in some trials (7; 16), others rule out an influence (2).  
The early anastomotic leakage rate has been reported as 8-18% after neoadjuvant treatment 
and is thereby no different from rates in non-irradiated patients (Table 3) (2; 7; 10; 17; 18). A 
correlation between neoadjuvant treatment and anastomotic leakage rate cannot be seen in a 
single study (2; 7; 9; 10; 17). However, in a population-based study from Sweden, the 
multivariate analysis of 432 out of 6833 patients revealed preoperative radiation to be an 
independent risk factor for anastomotic leakage (19). The restriction of this publication, 
however, is the fact that the large majority of these operations were performed without 
TME. Though, the influence of this fact is in this regard not known.  
Besides this, two single-centre studies report a positive correlation between the preoperative 
regression grade and the risk of anastomotic leakage (Fig. 1) (20; 21).  
One main problem of anastomotic leakage reporting is the fact that there is no definition of 
leakage that has to be reported (Fig. 2/3). While some studies report all clinical apparent 
leakages as well as the abscess around the anastomosis as leakage (7; 21), others do differ 
between clinical and radiological leakage (20). Some do not define what they count as 
leakage (2), others just allude to those complications that require reintervention (9).  
Until now, the influence of intensified chemoradiation using oxaliplatin is described by only 
one phase III trial (14). In this single trial, the rate of anastomotic leakage is no different 
between patients who received capecitabine and those with additional oxaliplatin (14). 
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Fig. 1. Rectal cancer after neoadjuvant chemoradiation. Downstaging was 
histopathologically proven; a distinct fibrosis can be seen macroscopically.  
 
 
Fig. 2. Radiographically proven old anastomotic leakage that presented years later with 
outlet obstruction.  
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Fig. 3. Radiographically proven anastomotic leakage with extraluminal contrast agent 
(arrow).  
 
Reference No. of 
patients 
Therapy strategy Overall rate of 
postoperative 
complications (%) 
P value 
Marijnen 
2002 
695 vs. 719 5x5 Gy versus 
TME 
48 vs. 41 0.008 
Bujko  
2004 
155 vs. 157 5x5 Gy versus 
preoperative 
chemoradiation 
(5-FU) 
23 vs. 15* 0.12 
Bosset  
2004 
398 vs. 400 45 Gy versus 
preoperative 
chemoradiation 
(5-FU) 
22.2 vs. 22.8* n.s. 
Gérard  
2006 
367 vs. 375 45 Gy versus 
preoperative 
chemoradiation 
(5-FU) 
26.9 vs. 20.9 n.s. 
Sauer  
2004 
404 vs. 394 Pre-  versus 
postoperative 
chemoradiation 
(5-FU) 
36 vs. 34 0.68 
Gérard  
2010 
293 vs. 291 Cap vs. CapOx 
preoperative 
chemoradiation 
33.8 vs. 30.6 n.s. 
* Complication criteria not defined 
Table 2. Postoperative complications in randomised trials.  
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Reference Anastomotic 
leakage rate (%)
P value Surgical reintervention 
rate (%) 
P value 
Marijnen 
2002 
11 vs. 12 n.s. 14.8 vs. 13.6 n.s. 
Bujko  
2004 
Not reported  12 vs.9 0.38 
Bosset  
2004 
Not reported  Not reported  
Gérard  
2006 
7.6 vs. 7.4 n.s. Not reported  
Sauer  
2004 
11 vs. 12 0.77 Not reported  
Gérard  
2010 
18.9 vs. 16.7 * n.s. 12.9 vs. 12.5 0.9 
*Rate of surgically treated anastomotic fistula; Additional conservatively treated fistula: 8.5% vs. 7.7%; n.s.  
Table 3. Anastomotic leakage rate and surgical reintervention rate in randomised trials. 
The rate of diverting stoma creation is not mentioned in some large trials (2; 10; 11; 22). 
Others merely report the late rate of permanent stoma (23). In fact, only some studies have 
reported the rate of defunctioning stomas and identified in addition the different rates 
between stoma created initially and those created subsequently as a result of another 
complication (7; 17); altogether, the rates are hardly comparable.  
Mortality rate is the same in patients with or without neoadjuvant treatment (1; 2; 9 - 11; 18; 
24). It is to be noted that the intensified neoadjuvant chemoradiation with oxaliplatin does 
not influence the mortality rate (13; 14). 
4. Late side effects 
Improving the oncological results of rectal cancer patients also directed the scientific focus 
on late side effects, late functional results and long-term quality of life.  
However, results of the late functional investigations of 597 patients of the Dutch TME trial 
were disappointing (Tab.4) (25). Patients with a local recurrence were excluded from this 
follow-up, so that the functional results were not disease-related. 5 years after the primary 
treatment, 68% of irradiated patients suffered from incontinence during the day and 32% 
from incontinence at night. These were 24% resp. 15% more than in non-irradiated patients. 
There were statistically significant differences in terms of bowel frequency, blood loss and 
mucus loss (25). Pad use as evidence of incontinence was evaluated in 56% of the irradiated 
patients while 33% of the directly operated patients had the same need (p<0.001) (25). 
Fractionated defecation with the sensation of incomplete evacuation is elicited in 35-58% of 
irradiated patients (26–28). Irradiated patients were significantly impaired in their daily 
activities and social function (29).  
It is understandable from the information above that irradiated patients without a stoma 
were significantly less satisfied than non-irradiated patients. If patients had a stoma, the rate 
of satisfaction did not differ between those that were radiated and those that were non-
irradiated (25). It is to be noted that impairment of the sphincter function may have been so 
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severe that significantly more patients would have been satisfied if they had had a stoma 
than if they had not (25). This result is interesting due to the fact that sphincter-preservation 
is seen to be one of the main objectives of neoadjuvant and surgical therapy (2). It is often 
suggested that patients with a stoma generally have lower quality of life and as a 
consequence, sphincter-sparing surgery has been forced (5). Already when low anastomosis 
started coming up, the problem of reduced social functioning of both colostomy and 
impaired anal sphincter was seen and could not be clearly weighed up (30). It is meaningful 
that the surgical and oncological aims seem not to correspond completely with the demand 
of the patients (31). In a survey of healthy individuals it turned out that the majority would 
prefer a treatment with better functional outcome even when they would have to accept a 
higher risk of local recurrence (31). In another study was revealed that patients and even 
oncologist and surgeons would trade survival for quality of life. 52% of the questioned 
patients – and 88 and 90% resp. of the surgeons and oncologist - would trade life to avoid 
colostomy (6).  
A Norwegian study that evaluated the functional outcome of 199 patients 4.8 years after 
initial treatment found a significant correlation between incontinence of liquid stool and 
overall quality of life (29). In the really long-term results, 15 years after radiation, 69% of the 
irradiated versus 43% of the non-irradiated patients had incontinence complications (32). 
More than twice as many patients suffered from fecal incontinence after irradiation. 
However, this data was generated from the Swedish Rectal Cancer Trial, which means that 
the patients were operated on without using the TME procedure. Although there is no 
randomised trial that would compare conventional rectal cancer surgery and TME 
procedure – and due to the definitely favourable results of the TME procedure there will 
never be one – several smaller in-hospital series compare functional results of the two 
procedures. In those studies the postoperative impairment of urination and genital function 
rather improved when TME was introduced (33;34). 
The poor functional results seem to be the same or even worse following chemoradiation 
(Tab. 4) (35; 36). Good anal function was stated in one study that compared chemoradiation 
with radiation in 11% versus 30%, resp. of the patients seen (p=0.04) (36).  
The results concerning urinary incontinence after radiation are inconsistent. While the late 
results of the Dutch TME study do not find a correlation to preoperative radiation, this 
correlation is to be found in a Norwegian study of 199 irradiated patients (25; 29; 37).  
From the Dutch TME trial, we know that former sexually active male and female patients 
are significantly impaired in their sexual activity in an evaluation two years after surgery 
(38). Two other studies that described a significant lack of lubrication or more vaginal 
dryness, dyspareunia and reduced vaginal dimension in irradiated patients confirmed this 
data. However, women were not concerned about their sexual life (36; 39). It is to be noted 
that one study did not discriminate between pre- and postoperative irradiation (39) and the 
other one was performed with initially nonresectable rectal cancer (36).   
In male patients, both erection and ejaculation functions were impaired after 5x5Gy 
radiation therapy (38). As the impaired sexual functions differ significantly in direct 
comparison to only operated patients, there must be a direct influence from radiation in 
addition to the possible surgical damage to the pelvic autonomic nerves. Whether or not this 
influence consists of radiation damage to the nerves itself, a postirradiated reduced 
tolerance to surgery-caused ischemia or to technically hindered surgery after radiation 
cannot be clarified (40).  
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Reference No. of 
patients 
Therapy 
strategy 
Follow-up 
(yrs; 
median) 
Fecal 
incontinen
ce (%) 
P value 
Peeters 
2005 
177 vs. 185 5x5 Gy versus 
TME 
5.1 62 vs. 38* <0.001 
Pollack 
2006 
21 vs. 43 5x5 Gy versus 
conventional 
surgery 
14 57 vs. 26 0.013 
Brændengen 
2006 
18 vs. 19 Preop. RTX 
versus RCTX 
4-12 58 vs. 38° 
75 vs. 56 ∆ 
 
Coco 
2007 
100 50.4Gy 12 46 ∆ 
14 ¥ 
 
Urso † 
2006  
12 Pre- and 
postoperative 
19 mths 75 ¥  
Bruheim † 
2010  
69 vs. 240 Pre- and 
postoperative 
versus TME 
4.8 71 vs. 58∆ 
52 vs. 13 ¥ 
0.01 
<0.001 
* Incontinence by day; Incontinence at night: 32 vs. 17%(P=0.001); ° Incontinence to stool;  
∆ Incontinence to gas; ¥ Defined as: requirement of pad use 
†Urso (2006): Preoperative chemoradiation (50.4Gy) with 5-FU and oxaliplatin, postoperative 5-FU-
based chemotherapy. Bruheim (2010): Pre- or postoperative radiation (50Gy) with chemotherapy (in 
40% of neoadjuvant radiation; in 75% of adjuvant radiation).  
Table 4. Late functional results; RTX: radiation therapy; RCTX: radiochemotherapy 
Hip fracture is a rarely mentioned late complication but seems to be significantly increased 
in irradiated patients (29; 41). In the Norwegian study by Bruheim, et al. the incidence of 
pelvic fracture was five times higher in the irradiated patients (5% versus 1%) (29). 
Furthermore, in the group of irradiated patients female sex seems to be the only 
independent predictor for fracture (42). However, in the late follow-up of the Dutch TME 
trial hip fracture rate did not differ between irradiated and non-irradiated patients (25).  
Reports concerning second malignancies following radiation of the Swedish Rectal Cancer 
Trial (43) are refuted by a large population-based analysis of 20,910 patients that showed 
that the rare event of second primary malignancies is not more frequent in irradiated 
patients (44). The occurrence of a second malignancy in an adjacent organ of the irradiated 
volume seems to be weighted between the radiation-induced malignancies and those 
spontaneous malignancies accidentally avoided by radiation (44).  
Anal stricture or late anastomotic stricture is reported in some publications (35; 45). 
However, a difference between irradiated and non-irradiated patients is not seen in the 
long-term follow-up of the Dutch TME trial (25) and a difference between patients with 
preoperative and postoperative chemoradiation cannot be seen either (45).  
5. Discussion 
Besides the side effects reported above there are few further thoughts regarding 
neoadjuvant treatment as a source of possible harm. With the current staging methods an 
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overtreatment is performed in probably 18% of the patients, most of them wrongly staged as 
cT3N0 (2). However, this overtreatment is intentional as 22% of the pT3 tumours had a 
previously undetected involvement of mesorectal lymph nodes and would have poorer 
local control with postoperative treatment (46). This means that at present the incidence of 
side effects in overtreated patients who would require nothing other than surgery 
unfortunately has to be accepted to include most of the patients to neoadjuvant treatment 
who really need it.  
Another cause of medical discomfiture is the group of patients without any signs of 
regression. Those non-responders do have the correct indication for the treatment but 
instead of benefit they only see the side effects of the treatment. To date, there is no 
predictive resistance marker that could exclude those patients from neoadjuvant treatment.  
For short-course radiotherapy where there is a short amount of time until the operation it must 
be taken into account that there is no downstaging. Patients in whom an involvement of the 
circumferential margin is suspected should maybe treated with chemoradiation as a 
preference. In case of showing an involved circumferential resection margin after neoadjuvant 
treatment the long-term is even worse than having an involved margin after direct surgical 
resection (47;48). Chemoradiation alone can provide preoperative downstaging, however, the 
long-term functional results are even worse than those following radiation. 
Another critical point is that the improved local control of neoadjuvant short-course 
radiation has to be put into a certain sense of perspective by the fact that the oncological 
benefit may be only valid for mid-rectal cancers from 5 to 10 cm from the anal verge (47). 
Conversely, the low rectal cancer patients and those with tumours in the upper third seem 
not to profit from the benefit that short-course radiation might offer.   
6. Conclusion 
In addition to acute side effects that seem to be feasible, it is assumed that there are surgical 
and other perioperative complications that are not reported as a matter of routine. It is 
evident, that a regular report system of acute and late side effects concerning medical and 
surgical problems is not implemented yet. 
In particular the late complications appear to limit the patient in their functional abilities 
and quality of life. Moreover, the late side effects are probably still underestimated. To date, 
the impairment of social life by poor anorectal function and the psychological consequences 
of sexual dysfunction have barely been evaluated. It has to be assumed by a lack of studies 
evaluating late side effects, that the unreported number of cases exceeds the published ones. 
A certain number of unreported cases should however also be assumed as many patients do 
not answer honestly due to a sense of shame. Unfortunately, the evidenced poor functional 
results after rectal cancer surgery seem to be worsened by neoadjuvant treatment. It is easier 
said than done, but the patients have to be individually balanced in terms of their potential 
oncological benefit against the probable functional deficiency that is likely to compound 
over the years. 
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